Acute Respiratory Distress Syndrome
Conditions
Keywords
ARDS
Brief summary
Evaluate the safety, tolerability, efficacy and pharmacodynamics&pharmacokinetic properties of CT303 in patients with ARDS.
Detailed description
This study is a multi-center, open-label, dose-escalation and dose-finding phase 1 clinical trial. The primary purpose is to evaluate the safety and tolerability of CT303 and the Secondary purpose is to evaluate the efficacy of CT303 in patients with ARDS. And the exploratory purpose is to evaluate pharmacodynamics properties pharmacokinetic properties of CT303 in patients with ARDS.
Interventions
GENETICCT303
Once a time, intravenous injection * CT303 Starting Dose : 1.0\*10\^6 cells/kg * CT303 Increasing Quantity Dose : 2.0\*10\^6 cells/kg
Sponsors
GC Cell Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 19 years old * Patients who meet the ARDS criteria according to the Berline definition 1. within 1 week of a known clinical insult or new or worsening respiratory symtoms 2. Bilateral opacities not fully explained by effusions, loar/lung collapse, or nodules 3. Respiratory failure not fully explained by cardiac failure or fluid overload 4. oxygenation corresponding to mild, moderate, severe * Patients requiring positive pressure ventilation using an endotracheal tube * Patients or legal representative signed Informed consent form
Exclusion criteria
* Greater than 96 hours since first meeting ARDS criteria * Patients who was previously administered mesenchymal stem cell therapy products or other cell therapy products * Patients with the following medical history or comorbid condition 1. medical history 1. Patients who had an organ transplant or bone-marrow transplantation 2. Patients who had a pneumonectomy 3. a maligant tumor within 5 years 4. a deep vein thrombosis or pulmonary embolism with in 6 months 5. a trauma within 7 days 2. comorbid condition 1. Patients with AST or ALT exceeding 5 times the upper limit of the normal range 2. eGFR ≤ 29mL/min or Patients requiring continuous renal replacement therapy 3. severe chronic respiratory disease 4. WHO functional assessment class III/IV pulmonary hypertension 5. Severe cardiac insufficiency 6. QTc \> 480msec 7. chronic underlying diseases * viral hepatitis type B or type C, or positive HIV test * Patients using extracorporeal life support devices or high-frequency oscillatory ventilation * Moribund patients expected to die within 48 hours * Patients who refuse or are likely to refuse life-sustaining treatment * Fertile women or men who disagree a continence and a contraception * Patients with a history of hypersensitivity reaction * Patients participating in clinical trials within 4 weeks * Patients determined by the investigator to be inappropriate to participate in this clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Drug Reaction incidence rate | Day 0 to Day 28 | Evaluate safety through the incidence rate of adverse drug reactions corresponding to criteria for stopping the dose increasing. |
Countries
South Korea
Outcome results
None listed